One or more of the required application components couldn’t be loaded. Please, refresh the page.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
12:52 AM
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CLRB

Cellectar Biosciences Inc

Last Close
Mar 20 • 04:00PM ET
0.3801
Dollar change
-0.0056
Percentage change
-1.45 		%
Healthcare • Biotechnology • USA • NASD
Peers: KPTI GLYC APTO CLLS IMUX ONCT MEIP CRIS PSTV SLS
 | Held by: VTI VXF IWC
Scroll to Statements
Index- P/E- EPS (ttm)-1.51 Insider Own1.67% Shs Outstand46.08M Perf Week26.87%
Market Cap17.51M Forward P/E- EPS next Y-0.70 Insider Trans4.06% Shs Float45.31M Perf Month14.83%
Income-44.58M PEG- EPS next Q-0.16 Inst Own11.18% Short Float4.34% Perf Quarter47.50%
Sales0.00M P/S- EPS this Y47.54% Inst Trans21.70% Short Ratio0.99 Perf Half Y-81.99%
Book/sh0.30 P/B1.27 EPS next Y-8.85% ROA-237.45% Short Interest1.97M Perf Year-88.65%
Cash/sh0.51 P/C0.75 EPS next 5Y16.51% ROE-4693.38% 52W Range0.22 - 4.17 Perf YTD27.12%
Dividend Est.- P/FCF- EPS past 5Y40.27% ROI-277.14% 52W High-90.88% Beta0.58
Dividend TTM- Quick Ratio2.58 Sales past 5Y0.00% Gross Margin- 52W Low69.69% ATR (14)0.03
Dividend Ex-Date- Current Ratio2.58 EPS Y/Y TTM56.38% Oper. Margin- RSI (14)65.75 Volatility11.64% 9.41%
Employees11 Debt/Eq0.03 Sales Y/Y TTM- Profit Margin- Recom1.50 Target Price5.67
Option/ShortYes / Yes LT Debt/Eq0.03 EPS Q/Q87.41% Payout- Rel Volume0.44 Prev Close0.39
Sales Surprise- EPS Surprise80.14% Sales Q/Q- EarningsMar 13 BMO Avg Volume1.98M Price0.38
SMA2021.13% SMA5030.42% SMA200-75.57% Trades Volume872,639 Change-1.45%
Date Action Analyst Rating Change Price Target Change
Dec-05-24Resumed Ladenburg Thalmann Buy $13
Jul-01-20Initiated Oppenheimer Outperform
Jan-21-20Resumed ROTH Capital Buy $10
Sep-13-19Initiated ROTH Capital Buy
Dec-21-16Initiated Ladenburg Thalmann Buy $2.70
Mar-18-25 09:40AM
Is Cellectar Biosciences (CLRB) Stock Outpacing Its Medical Peers This Year?
(Zacks) +11.97%
Mar-14-25 03:04AM
Cellectar Biosciences Inc (CLRB) Q4 2024 Earnings Call Highlights: Strategic Restructuring and ...
(GuruFocus.com) +5.34%
Mar-13-25 11:43PM
Q4 2024 Cellectar Biosciences Inc Earnings Call
(Thomson Reuters StreetEvents) -5.37%
07:05AM
Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update
(GlobeNewswire)
Mar-11-25 08:05AM
Cellectar Biosciences to Present at the 37th Annual Roth Conference
(GlobeNewswire)
08:05AM Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.Finviz Elite
Mar-05-25 08:05AM
Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025
(GlobeNewswire) +6.56%
Feb-05-25 08:05AM
Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
(GlobeNewswire)
Jan-12-25 06:00PM
Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare Conference
(GlobeNewswire)
Dec-11-24 11:25AM
Cellectar Biosciences Stock Plunges As Cancer-Focused Cancer Firm Pursues Strategic Options
(Benzinga) -76.16%
Dec-10-24 05:00PM
Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring
(GlobeNewswire) -5.19%
Nov-21-24 08:00AM
NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225)
(Business Wire)
Nov-19-24 01:39AM
Q3 2024 Cellectar Biosciences Inc Earnings Call
(Thomson Reuters StreetEvents) -9.04%
Nov-18-24 07:05AM
Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update
(GlobeNewswire)
Nov-14-24 08:05AM
Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225
(GlobeNewswire)
Nov-12-24 08:05AM
Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer
(GlobeNewswire)
04:05PM Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.Finviz Elite
Nov-11-24 04:05PM
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024
(GlobeNewswire)
Nov-07-24 06:40AM
Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024
(GlobeNewswire)
Nov-01-24 05:00PM
Cellectar Biosciences Announces Compliance Regarding Filing of Form 10-Q
(GlobeNewswire)
Aug-26-24 06:40AM
Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom's Macroglobulinemia
(GlobeNewswire)
Aug-23-24 05:00PM
Cellectar to Restate Previously Issued Financial Statements Company Announces Receipt of Expected Delinquency Notification Letter from Nasdaq
(GlobeNewswire)
Aug-13-24 06:40AM
Cellectar Biosciences Reports Financial Results for Q2 2024 and Provides a Corporate Update
(GlobeNewswire) +8.60%
Aug-08-24 05:15PM
UPDATE -- Cellectar Biosciences to Announce Second Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024
(GlobeNewswire)
04:05PM
Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024
(GlobeNewswire)
Jul-23-24 06:40AM
Cellectar Biosciences' Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom's Macroglobulinemia Pivotal Study with 78% of Major Response Patients Remaining Progression Free at 18 Months
(GlobeNewswire) -18.54%
Jul-22-24 06:40AM
Cellectar Biosciences Announces Exercise of Tranche B Warrants and Purchase of New Warrants for Approximately $19.4 million with the Potential to Raise Up to an Additional $73.3 Million
(GlobeNewswire) +19.84%
Jun-27-24 06:40AM
Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its CLOVER WaM Pivotal Trial and Waldenstrom's Macroglobulinemia Market Landscape
(GlobeNewswire) -19.38%
May-29-24 06:40AM
Cellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis Fungoides
(GlobeNewswire)
May-15-24 08:18AM
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q1 2024 Earnings Call Transcript
(Insider Monkey) +5.66%
03:43AM
Q1 2024 Cellectar Biosciences Inc Earnings Call
(Thomson Reuters StreetEvents)
03:02AM
Cellectar Biosciences Inc (CLRB) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
(GuruFocus.com)
10:53AM Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.Finviz Elite
May-14-24 10:53AM
CLRB Stock Earnings: Cellectar Biosciences Misses EPS for Q1 2024
(InvestorPlace)
06:40AM
Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update
(GlobeNewswire)
May-08-24 06:40AM
Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day
(GlobeNewswire)
May-07-24 06:40AM
Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024
(GlobeNewswire)
Mar-28-24 10:33AM
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2023 Earnings Call Transcript
(Insider Monkey) +9.49%
Mar-27-24 10:09PM
Q4 2023 Cellectar Biosciences Inc Earnings Call
(Thomson Reuters StreetEvents) -5.58%
10:53AM
CLRB Stock Earnings: Cellectar Biosciences Beats EPS for Q4 2023
(InvestorPlace)
06:40AM
Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update
(GlobeNewswire)
Mar-20-24 06:40AM
Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024
(GlobeNewswire)
Mar-14-24 08:52AM
Cellectar Biosciences to Present at the 36th Annual Roth Conference
(GlobeNewswire)
Mar-04-24 06:40AM
Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer
(GlobeNewswire)
Feb-07-24 06:40AM
Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
(GlobeNewswire)
Jan-30-24 06:40AM
Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study
(GlobeNewswire) -5.70%
Jan-25-24 06:40AM
Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million
(GlobeNewswire) +6.85%
Jan-22-24 06:40AM
Cellectar Biosciences Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom's Macroglobulinemia Patient
(GlobeNewswire)
Jan-16-24 06:40AM
Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical Data
(GlobeNewswire) +5.41%
Jan-12-24 06:44AM
Cellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D. on January 19, 2024 to Discuss Iopofosine I 131 Pivotal Topline Results
(GlobeNewswire)
Jan-11-24 06:40AM
Cellectar Biosciences Partners with MiBA, a Data Subsidiary of American Oncology Network, to Advance the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting
(GlobeNewswire)
Jan-08-24 08:37AM
Why Is Cellectar Biosciences (CLRB) Stock Up 16% Today?
(InvestorPlace) +18.08%
06:40AM
Cellectar's blood cancer therapy succeeds in trial
(Reuters)
06:30AM
Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom's Macroglobulinemia
(GlobeNewswire)
Jan-03-24 08:30AM
Cellectar Biosciences to Announce Top-line Data from WM Pivotal Trial on January 8, 2024
(GlobeNewswire)
Dec-19-23 08:30AM
Cellectar Biosciences Expands Iopofosine I 131 Collaboration with Wisconsin Alumni Research Foundation
(GlobeNewswire)
Dec-12-23 08:30AM
Cellectar Biosciences Strengthens Intellectual Property Protection for its PDC Platform
(GlobeNewswire)
Dec-05-23 08:30AM
Cellectar Biosciences to Present at the Targeted Radiopharmaceuticals Summit Europe
(GlobeNewswire)
Nov-04-23 12:36PM
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q3 2023 Earnings Call Transcript
(Insider Monkey)
Nov-02-23 07:30AM
Cellectar to Release Top-line Data from WM Pivotal Trial During the JP Morgan Healthcare Conference the Week of January 8, 2024
(GlobeNewswire)
Oct-25-23 08:00AM
Cellectar Biosciences Partners with Florida Cancer Specialists & Research Institute to Support the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting
(GlobeNewswire)
Oct-24-23 08:00AM
Cellectar Biosciences to Announce Third Quarter Earnings Results and Host a Conference Call on Thursday, November 2, 2023
(GlobeNewswire)
Oct-17-23 08:00AM
Cellectar Biosciences Expands Commercialization Leadership Team Ahead of Pivotal Data for Iopofosine I-131 in Waldenstrom's Macroglobulinemia
(GlobeNewswire)
Oct-02-23 06:35AM
Cellectar Biosciences Expands Global Intellectual Property Portfolio with Four Patent Grants
(GlobeNewswire) +8.33%
Sep-18-23 08:40AM
Cellectar Biosciences Receives European Medicines Agency Priority Medicines (PRIME) Designation for Iopofosine for Waldenstroms Macroglobulinemia
(GlobeNewswire)
Sep-11-23 06:30AM
Cellectar Biosciences Announces Closing of up to Approximately $103 Million Private Placement Financing
(GlobeNewswire)
Sep-05-23 08:21AM
Cellectar Biosciences Announces up to Approximately $103 Million Private Placement Financing
(GlobeNewswire) +36.26%
Aug-14-23 08:40AM
Cellectar Reports Financial Results for Second Quarter 2023 and Provides a Corporate Update
(GlobeNewswire)
Jun-30-23 09:40AM
Is Cellectar Biosciences (CLRB) Outperforming Other Medical Stocks This Year?
(Zacks) +5.41%
Jun-28-23 08:30AM
Cellectar Biosciences Highlights Promising Interim Data from Its Ongoing Study of Iopofosine I 131 in Multiple Myeloma in an Oral Presentation at the SNMMI Annual Meeting
(GlobeNewswire)
Jun-12-23 08:30AM
Cellectar Provides a Research and Development Program Summary
(GlobeNewswire)
May-04-23 09:22AM
UPDATE -- Cellectar Reports Financial Results for First Quarter 2023 and Provides a Corporate Update
(GlobeNewswire)
08:40AM
Cellectar Reports Financial Results for First Quarter 2023 and Provides a Corporate Update
(GlobeNewswire)
Mar-09-23 08:40AM
Cellectar Reports Financial Results for Year Ended 2022 and Provides a Corporate Update
(GlobeNewswire) -10.53%
Mar-08-23 04:05PM
Cellectar to Participate at Upcoming Banking Conferences
(GlobeNewswire)
Feb-28-23 08:30AM
Cellectar Biosciences Reports Complete Response in a Relapsed/Refractory CNS Lymphoma Patient
(GlobeNewswire)
Feb-15-23 08:30AM
Cellectar Biosciences Hires Dr. Andrei Shustov as New Senior Vice President, Medical
(GlobeNewswire)
Nov-30-22 08:30AM
Cellectar Biosciences Announces Shane Lea as Chief Commercial Officer
(GlobeNewswire)
Nov-21-22 08:30AM
Cellectar Biosciences Announces Presentation of Data on CLR 12120 Series of Targeted Alpha-Emitting Therapies at the 13th Annual World ADC Conference
(GlobeNewswire)
Nov-16-22 08:30AM
Cellectar Announces Resolution of Breach of Contract and Intellectual Property Dispute
(GlobeNewswire)
Nov-03-22 08:30AM
Cellectar Reports Financial Results for Third Quarter 2022 and Provides a Corporate Update
(GlobeNewswire) -6.86%
Oct-25-22 04:30PM
Cellectar Biosciences Announces Closing of Concurrent Registered Direct and Private Placement Offerings of Approximately $10.7 Million Priced At-The-Market Under Nasdaq Rules
(GlobeNewswire) -5.21%
Oct-21-22 08:30AM
Cellectar Biosciences Announces Concurrent Registered Direct and Private Placement Offerings of Approximately $10.7 Million Priced At-The-Market Under Nasdaq Rules
(GlobeNewswire) -7.14%
Sep-22-22 08:30AM
Cellectar Awarded $2 Million Grant to Expand Its Ongoing Phase 1 Study of Iopofosine I 131 in Pediatric Brain Tumors
(GlobeNewswire) -9.05%
Sep-13-22 08:30AM
Cellectar Announces Publication of Data from Its Expansion Cohort of the Phase II CLOVER-1 Study Iopofosine I-131 in Relapsed/Refractory Multiple Myeloma in Natures Blood Cancer Journal
(GlobeNewswire)
Aug-30-22 02:55PM
Will Cellectar Biosciences (NASDAQ:CLRB) Spend Its Cash Wisely?
(Simply Wall St.)
Aug-05-22 08:30AM
Cellectar Reports Financial Results for Second Quarter 2022
(GlobeNewswire)
Jul-21-22 04:15PM
Cellectar Announces Stock Consolidation
(GlobeNewswire) +5.43% -20.60%
Jun-20-22 09:22AM
10 Best Biotech Penny Stocks To Buy Now
(Insider Monkey)
May-10-22 08:30AM
Cellectar Reports Financial Results for First Quarter 2022 and Provides a Corporate Update
(GlobeNewswire) -8.06%
Apr-26-22 08:00AM
Cellectar Biosciences Announces Positive DMC Review of Pivotal Trial of Iopofosine in Waldenstroms Macroglobulinemia
(GlobeNewswire) -6.32%
Apr-12-22 08:30AM
Cellectar Biosciences Announces Key Commercial Team Appointments
(GlobeNewswire)
Mar-23-22 06:35PM
Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Invest In Growth?
(Simply Wall St.)
Mar-21-22 08:30AM
Cellectar Reports Financial Results for Year Ended December 2021 and Provides a Corporate Update
(GlobeNewswire) +15.81%
Mar-10-22 04:05PM
Cellectar to Participate at Upcoming Banking Conferences
(GlobeNewswire)
Feb-23-22 08:00AM
Cellectar Biosciences Announces Executive Leadership Changes
(GlobeNewswire)
Jan-17-22 09:40AM
Is CanFite Biopharma Ltd (CANF) Outperforming Other Medical Stocks This Year?
(Zacks)
07:40AM
Zacks.com featured highlights include: RentACenter, U.S. Physical Therapy, Cellectar Biosciences, Toro and Zymeworks
(Zacks)
Jan-14-22 06:27AM
Ride on Rising P/E Investing With These 5 Top-Ranked Stocks
(Zacks)
Jan-04-22 08:30AM
Cellectar to Participate in Fireside Chat at the H.C. Wainwright Bioconnect Conference
(GlobeNewswire)
Dec-13-21 08:30AM
Cellectar Presented Data from its Ongoing Phase 2 CLOVER-1 Study of Iopofosine I-131 at the 63rd ASH Annual Meeting and Exposition
(GlobeNewswire) -7.32%
Dec-08-21 08:30AM
Cellectar Biosciences Announces Poster Presentation at the 63rd American Society for Hematology Annual Meeting and Exposition
(GlobeNewswire) +9.64%
Nov-16-21 08:30AM
Cellectars Iopofosine I-131 Exhibits Signals of Efficacy in Phase I Study for Pediatric Brain and Solid Tumors
(GlobeNewswire) -5.02%
Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124, which could detect tumors and metastases in a broad range of cancers, and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded on June 24, 1996 and is headquartered in Florham Park, NJ.

Institutional Ownership

VANGUARD GROUP INC4.18%
ADAR1 Capital Management, LLC1.42%
Squarepoint Ops LLC1.26%
UBS Group AG0.91%
GEODE CAPITAL MANAGEMENT, LLC0.85%
BlackRock, Inc.0.56%
Altium Capital Management LLC0.52%
BANK OF AMERICA CORP /DE/0.50%
JPMORGAN CHASE & CO0.44%
MORGAN STANLEY0.43%
Insider Trading Volume
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Longcor JarrodChief Operating OfficerJan 10 '25Buy0.2830,0008,40083,141Mar 12 09:44 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • help • privacy • do not sell my data
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.